Abstract Details

Title The Philadelphia Brief Assessment of Cognition as a Measure of Cognitive Impairment in Parkinson's Disease

Topic Movement Disorders

Presentation(s) P04 - (-)

Poster/Presentation
Number 166

Objective

Background BACKGROUND: The Philadelphia Brief Assessment of Cognition (PBAC) is a brief dementia screening instrument testing five cognitive domains: executive function, language, visuospatial skills, episodic memory, and social behavior. The PBAC has been validated as a screening measure for dementia in patients with Alzheimer's disease and frontotemporal degeneration. In Parkinson's disease (PD), the Montreal Cognitive Assessment (MoCA) and Mattis Dementia Rating Scale (DRS) are widely utilized as measures of cognitive impairment. PBAC is briefer to administer than the DRS and provides subscale scores not available in the MoCA. The current study examined the PBAC relative to the MoCA and DRS in PD patients with a range of cognitive impairment.

Design/Methods DESIGN/METHODS: Sixty patients with PD, PD and mild cognitive impairment, and PD dementia were recruited from the University of Pennsylvania movement disorders and cognitive neurology clinics. Patients completed the PBAC, MoCA, and DRS, as well as the following battery of standard neuropsychological tests: FAS Verbal Fluency (executive), Boston Naming Test (verbal), Benton Judgment of Line Orientation (visuospatial), and Hopkins Verbal Learning Test (memory). The average interval between tests was 33.7 (SD=17.9) days.

Results RESULTS: The PBAC was highly correlated with the MoCA (r=0.834, p<0.05) and the DRS (r=0.824, p<0.05). The PBAC subscales were significantly correlated with standard neuropsychological tests from each domain (executive: r=0.812, verbal: r=0.538, visuospatial: r=0.508, memory: r=0.757; p<0.05 for all correlations).

Conclusions CONCLUSIONS: The PBAC provides overall dementia scores in PD as effectively as the MoCA and DRS, and also provides subscale scores within specific cognitive and behavioral domains. The PBAC is a valid test of cognitive impairment in PD.

Authors/Disclosures
PRESENTER	No disclosure on file
Jacqueline Rick	No disclosure on file
Jessica L. Kitain	No disclosure on file
Nizar Souayah, MD, FAAN (NJMS)	Dr. Souayah has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Takeda. Dr. Souayah has received publishing royalties from a publication relating to health care.
	No disclosure on file
Eduardo E. Benarroch, MD, FAAN (Mayo Clinic)	Dr. Benarroch has nothing to disclose.
Ashley Boller	No disclosure on file
	No disclosure on file
Danielle Weinberg	No disclosure on file
David J. Libon, PhD (Rowan Univerity)	No disclosure on file
Andrew D. Siderowf, MD	Dr. Siderowf has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boehringer-Ingelheim. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving as a Consultant for askbio. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving as a Consultant for capsida. Dr. Siderowf has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Parkinson Study Group. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Theravance. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurocrine. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Prilenia. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Wave. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurogastrix. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Prevail. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alerity. Dr. Siderowf has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Clintrex. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Inhibikase. Dr. Siderowf has a non-compensated relationship as a Scientific Advisory Board with NeuroPacs that is relevant to AAN interests or activities.
Murray Grossman, MD, FAAN (University of Pennsylvania)	Dr. Grossman has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology. The institution of Dr. Grossman has received research support from NIH.
Rachel Goldmann Gross, MD	No disclosure on file

��ɫ��

��ɫ��